20 results
8-K
EX-3.1
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-3.2
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-3.3
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-3.1
NGNE
Neurogene Inc
22 Sep 23
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
8:03am
8-K/A
EX-3.1
NGNE
Neurogene Inc
23 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:20pm
8-K
EX-3.1
rik8h5
30 Nov 22
Amendments to Articles of Incorporation or Bylaws
4:46pm
8-K
EX-3.1
wuqm0ularyaqccsud
13 Apr 20
Amendments to Articles of Incorporation or Bylaws
8:30am
8-K
EX-3.1
9n9e4fg5lndy7n rrg
12 Aug 19
Entry into a Material Definitive Agreement
8:01am
8-K
EX-3.1
6p97i4m13i 3rp4djikr
12 Mar 14
Amendments to Articles of Incorporation or Bylaws
12:00am
S-1/A
EX-3.6
f6gzcid18yy
28 Feb 14
IPO registration (amended)
12:00am
S-1/A
EX-3.5
tirfghstzks 81vb
28 Feb 14
IPO registration (amended)
12:00am
S-1/A
EX-3.3
vsppm4ttwnjyhygvaol
28 Feb 14
IPO registration (amended)
12:00am
S-1
EX-3.1
nbx65z6cdnpnvux1
28 Jan 14
IPO registration
12:00am
S-1
EX-3.2
wybnoc
28 Jan 14
IPO registration
12:00am
S-1
EX-3.3
050usuja69l
28 Jan 14
IPO registration
12:00am
DRS/A
EX-3
dhcfzjyi ed
24 Dec 13
Draft registration statement (amended)
12:00am
DRS
EX-3.1
d3uqjji1e
18 Nov 13
Draft registration statement
12:00am
DRS
EX-3.2
m4wyswps28c3gw34fhy
18 Nov 13
Draft registration statement
12:00am
- Prev
- 1
- Next